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JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2
occurs inmyeloproliferative neoplasms by diﬀerentmechanisms. As a consequence, JAK2 inhibitors have been designed to suppress
the cytokine signalling cascade caused by the constitutive activation of JAK2. In clinical trials, JAK2 inhibitors are eﬃcient in
decreasing spleen size, controlling clinical symptoms, and improving quality of life in patients with myeloproliferative neoplasms.
However, JAK2 inhibitors are unable to target uncommitted hematopoietic progenitors responsible of the initiation of the myelo-
proliferative disease. It is expected that, in order to cure the myeloproliferative disease, JAK2 inhibitors should be combined with
other drugs to target simultaneously diﬀerent pathways and to target the initiator hematopoietic cell population in myeloprolifera-
tive disorders. Taking advantage of the inhibition of the cytokine cascade of JAK2 inhibitors, these compounds are going to be used
not only to treat patients with hematological neoplasms but may also be beneficial to treat patients with rheumatoid arthritis or
other inflammatory diseases.
1. Introduction
Myeloproliferative neoplasms (MPNs) are clonal disorders
up to now characterized by the autonomous proliferation of
committed hematopoietic progenitors secondary to an aber-
rant activation of tyrosine kinase (TK) signalling pathways in
combination with an exaggerated response to hematopoietic
cytokines and growth factors [1, 2]. Constitutive activation of
TKs is a consistent molecular signature in cell proliferation.
Examples of Constitutive activation of TKs are seeing in solid
tumours [3, 4], rheumatoid arthritis [5], and hematopoietic
malignancies [6]. Known mechanisms of TK activation may
result from acquired heterozygote of homozygote point mu-
tations [7, 8], internal tandem duplications [9], and chromo-
somal translocations [10, 11]. The knowledge of the molec-
ular mechanism involved in the pathogenesis of chronic
myeloid leukemia (CML) [12] has allowed to elucidate the
molecular dissection of chronic proliferation in MPN. Using
CML as paradigm of constitutive activation of TK in chronic
myeloproliferation, James et al. sequenced the coding exons
and intron-exon junctions of JAK2 in 3 polycythemia vera
(PV) patients and 2 controls. In 2 of these patients a G-to-T
mutation at nucleotide 1849 in exon 12 was found, leading
to a substitution of valine to phenylalanine at position 617
(V617F). This mutation was not a polymorphism, but a
recurrent acquired mutation that was found in granulocytes,
erythroblasts, and platelets of 40 out of 45 PV patients but
not in any controls or patients with secondary erythrocytosis
[13]. JAK2V617F was also found in other BCR-ABL negative
MPN [14]. JAK2V617F occurs in the pseudokinase domain
of the JAK2 gene. The mutated pseudokinase domain is not
able to negatively regulate the kinase domain of JAK2, result-
ing in an autonomous activation of the JAK2 kinase domain
with subsequently persistent phosphorylation of STAT and
MAPK proteins [15, 16] and hyperstimulation of the cyto-
kine signalling pathway [17]. As a consequence, cells exp-
ressing the JAK2V617F mutation are hypersensitive to hema-
topoietic cytokine stimulation, resulting in an abnormal
erythroid-, myeloid-, and thromboproliferation. Moreover,
JAK2-deficient mice do not survive because of absence of
erythropoiesis. Myeloid progenitors of these mice fail to
respond to EPO, GM-CSF, and thrombopoietin stimulation
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[18]. These experiments demonstrate that JAK2 plays an
essential role in the development of normal hematopoi-
esis.
Not all patients with “classical” MPN carry the JAK2V6-
17F mutation. This mutation is present in almost all PV
patients, but only in half of the patients with essential thro-
mbocythemia (ET) and primary myelofibrosis (PMF), sug-
gesting that there are alternative routes of JAK-cytokine
signalling activation [14]. In the most prevalent BCR-ABL1
negative MPN (PV, ET, and PMF), up to now it is known that
JAK2 activationmay also occur by JAK2 mutations in exon 12
[19], by mutations in the inhibitory adaptor protein LNK
[20], or by a TEL-JAK2 chromosomal translocation that in-
duces erythropoietin-independent erythroid diﬀerentiation
and myelofibrosis [21]. Other mutations described in MPN
but also in other haematological malignancies are mutations
in the thrombopoietin receptor at codon 515 (MPL) [22], the
isocitrate dehydrogenase family genes (IDH), the additional
sex combs like 1 gene (ASXL1), the casitas B-lineage lym-
phoma proto-oncogene (CBL), the TET oncogene family
member 2 (TET2), and the Ikaros family zinc finger 1 gene
(IKZF1) [23]. These mutations promote hematopoietic pro-
liferation via other pathways than JAK-cytokine signalling
activation and they have been detected more frequently in
MPN other than PV, ET of PMF, myelodysplastic syndromes,
secondary acute myeloid leukemia, and blast-transformation
phase of MPN.
There is a relationship between the underlying genetic
mechanism of the MPN and the response to diﬀerent treat-
ments. For example, 40–50% of the patients with pri-
mary PMF and ET who carried JAK2V617F mutation had
decreases in proportion of JAK2-mutated DNA [24]. About
20% of the PMF and ET patients who carried MPL mutations
had no decreases in proportion of MPL-mutated DNA
when treated with JAK2 inhibitors but they did have it
when treated with biological response modifiers (pegylated-
interferon alpha 2a, lenalidomide, and prednisone) [24].
New biological properties of JAK2 are currently being
investigated. Recently, it has been demonstrated that JAK2
is not only localised in the cytoplasm of hematopoietic cells
where JAK2 plays a role in the cytokine signalling pathway,
but also in the nucleus of hematopoietic cells [25]. In the
nucleus, a hyperactive JAK2 induces phosphorylation of
the histone H3 at tyrosine residue 41 (H3Y41), releasing
the transcriptional repressor heterochromatin protein 1alfa
(HP1a) from chromatin and resulting in an activation of
transcription of genes repressed by HP1a, as the oncogene
LMO2. LMO2 might play a role in the pathogenicity ofMPN.
It is remarkable that H3Y41 phosphorylation requires a
hyperactive JAK2, implying that the activation of diﬀerent
pathways with diﬀerent JAK2 eﬀectors and diﬀerent target
genes is involved in the pathogenesis of MPN.
In the era of JAK2 inhibitors, this finding opens new pos-
sibilities for combined therapeutic targets (JAK2 inhibitors
and histone posttranslational modificators) that may benefit
patients with MPN [26].
2. Current Therapies for BCR-ABL1
Negative MPN (PV, ET, and PMF) Based on
JAK2 Inhibitors and Their Combinations
Hyper-activation of JAK2 is a critical step in the pathogenesis
of BCR-ABL1 negative, classical MPN.
Autonomous activation of the JAK2 kinase domain with
subsequently persisting phosphorylation of STAT andMAPK
proteins occurs in patients with and without JAK2V617F
mutations. JAK2 inhibitors have been designed to suppress
the cytokine signalling induced by a hyperactive cytoplasma-
tic JAK2 gene. JAK2 inhibitors compete for the ATP-binding
pocket of the tyrosine kinase domain of JAK2 [27]. Because
JAK2V617F mutation is localized outside the ATP-binding
site, JAK2 inhibitors do not discriminate between JAK2 and
JAK2-mutated genes [28]. In consequence, JAK2 inhibitors
can be used in patients with MPN independently of the JAK2
mutation status.
Nowadays, several JAK2 inhibitors are tested in clinical
trials in Europe and USA (INCB018424, TG101348, CYT387,
CEP-701, AZD1480, SB1518, and XL019) and others (NCB0-
16562, NVP-BSK805, and R723) are in preclinical develop-
ment.
INCB018424 known as Ruxolitinib is a potent and selec-
tive JAK1 and JAK2 inhibitor. It has been used in patients
with PMF, where INCB018424 downregulates proinflamma-
tory cytokines through the inhibition of JAK1 and suppresses
the phosphorylated signal of STAT3 through the inhibition of
JAK2, independently of the presence of JAK2V617Fmutation
[29].
In animal models of JAK2V617F mutation MPN, oral
INCB018424 markedly reduced splenomegaly and circulat-
ing levels of inflammatory cytokines and preferentially elim-
inated neoplastic cells, resulting in significantly prolonged
survival without myelosuppressive or immunosuppressive
eﬀects [30].
In patients with PMF treated with INCB018424, a signif-
icant reduction of constitutional symptoms and more than
50% reduction of splenomegaly occurred. Clinical benefits
were associated with a marked decrease of levels of circu-
lating inflammatory cytokines, although the load of JAK2V6-
17F was marginally reduced [29]. Myelosuppression grade 3
or 4 was observed in less than 10% of the patients.
TG101348, also known as SAR302503, is a selective small-
molecule JAK2 antagonist that inhibits primary hematopoi-
etic cells derived from patients with MPN and with JAK2V6-
17F, MPLW515K, JAK2 exon 12 mutations as well as muta-
tion negative patients [31]. In animal models of JAK2V617F
positive MPN, TG101348 reduced erythrocyte and leukocyte
counts, the extramedullary hematopoiesis, and myelofibrosis
without toxicities [31, 32]. Biologically, TG101348 reduced
the JAK2V617F disease burden, and it was demonstrated a
suppression of endogenous erythroid colony formation and
inhibition of phosphorylated STAT5 [31]. In patients with
myelofibrosis, TG101348 induced a reduction of the spleen
size according to the criteria of International Working Group
for Myelofibrosis Research and Treatment (IWG-MRT) [33]
and a normalization of blood counts after 6 and 12 cycles
Advances in Hematology 3
[34]. A significant decrease in JAK2V617F allele burden was
observed at 6 months in mutation-positive patients with a
consistent decrease at 12 months [34].
CYT387 is an ATP-competitive potent JAK1, JAK2, and
tyrosine kinase 2 (TYK2) inhibitor, at nanomolar concentra-
tions, more selective against JAK2 than against other tyrosine
kinases in comparison with other JAK2 inhibitors [35]. Its
eﬀect has been analyzed in cell lines harboring mutated
JAK2 alleles, showing an inhibition of growth of erythroid
colonies and erythroleukemia cells and inhibition of STAT5
phosphorylation.
In a murine MPN model, CYT387 normalized erythro-
cytes, leukocytes, spleen size, and restored physiologic levels
of inflammatory cytokines. Biologically, there was a reduc-
tion of the JAK2V617F allele burden. However, after cessing
therapy, JAK2V617F positive cells persisted and MPN relap-
sed [35].
CEP-701 known as Lestaurtinib is an Fms-like tyrosine
kinase 3 (FLT3) inhibitor in current use on acute myeloid
leukemia clinical trials and a JAK2 kinase inhibitor which
suppresses phosphorylation induced by JAK2 tyrosine
kinase. In patients with PV, CEP-701 inhibited growth of ex-
panded erythroid cells [36]. In 22 patients with PMF who
carried out the JAK2V617F mutation, CEP-701 induced a
modest clinical recovery with mainly improvement of the
spleen size. Biologically there was no improvement in bone
marrow fibrosis or JAK2V617F allele burden [37]. Mainly
toxicities have a high incidence of any grade of gastroin-
testinal toxicity in 9–72% of the patients and haematological
toxicity grade 3-4 in 14–23% of the patients [37].
JAK2 inhibitors can be compared with BCR-ABL1 inhi-
bitors, since both sort of drugs are TK inhibitors. Never-
theless, whereas BCR-ABL1 inhibitors are directed against
an aberrant fusion gene [38], JAK2 inhibitors are directed
against a gene which is present in normal cells and have an
important role in the development of normal hematopoiesis.
This means that adverse events are induced with JAK2 inhi-
bitors at doses to be able to control the myeloproliferative
phenotype, inducing often grade 3-4 hematological toxicity
as seen in clinical trials, limiting the clinical eﬃciency of
JAK2 inhibitors. Diﬀerent studies describe the incidence of
reversible grade 3 or 4 hematological toxicity between 3–35%
depending on the inhibitor specificity [34, 37, 39]. Other
common adverse events are gastrointestinal symptoms,
probably related to the inhibition of other tyrosine kinases.
The incidence of nausea, vomiting, and diarrhoea varies
between 5–70% depending on the compound [34, 37, 39].
Up to now it is known that JAK2 is a member of a family
of tyrosine kinases present in the cytoplasm of hematopoietic
cells. Recently, it has been demonstrated that JAK2 is also
present in the nucleus of hematopoietic cells where it indi-
rectly activates the expression of oncogenes as LMO2 [25].
It is not yet well known whether JAK2 inhibitors have a role
in the inhibition of the JAK2 nuclear function. In the next
years, the increasing clinical and biological experience with
JAK2 inhibitors will clarify their role.
Although imatinib treatment in CML cannot directly be
compared with JAK2 inhibition in MPN, it can be used as a
model of clinical experience with TK inhibitors. Therefore,
we can speculate about what it is going to happen with the
use of JAK2 inhibitors in the clinical practice. One might
expect the drug resistance to JAK2 inhibitors by acquisition
of mutations in the ATP-binding pocket of the TK domain
of JAK2 and/or via the amplification of JAK2. We can also
expect that JAK2 inhibitors are eﬃcient to alleviate the clini-
cal symptoms of patients with MPN, when used as mono-
therapy, but ineﬃcient to cure the disease as happened with
imatinib [40]. Clinical trials using JAK2 inhibitors for pa-
tients with myelofibrosis have demonstrated the eﬀectiveness
of these drugs to reduce clinical symptoms splenomegaly
and to improve quality of life. However, in these trials, JAK2
burden was slightly reduced, indicating that JAK2 inhibitors
are eﬃcient to block the cytokine pathway responsible of
the clinical symptoms in patients with MPN, but are not
enough eﬃcient to block the main molecular mechanism
that originates the disease. Recently, Mullally et al. [41], using
a JAK2V617F knock-in mouse MPN model, have shown that
JAK2 inhibitors are able to control the hyperproliferation of
committed hematopoietic progenitors in MPN, but are
unable to eliminate the cell population from which the ini-
tiator clone arises. This cell population has been identified
as noncommitted hematopoietic progenitors JAK2V617F+,
Lin−, Sca+ c-kit+ (LSK positive). JAK2 inhibitors may have
to be used in combination with drugs which target the LSK
positive noncommitted population to be able to cure MPN.
Given the fact that JAK2 inhibitors induce myelosuppres-
sion but cannot cure MPN, combinations with other com-
pounds that might have therapeutic synergy with JAK2 inhi-
bitors seem to be mandatory. In this sense, interferon-alpha
therapy is a good option to be associated to JAK2 inhibitors,
due to its multiple eﬀects on the regulation of immune mo-
dulatory cells, the expression of apoptotic genes, inhibition
of angiogenesis, suppression of the proliferation of hema-
topoietic progenitor cells, and promoting the cycling of
hematopoietic stem cells [42, 43]. It is thought that inter-
feron-alpha can also inhibit the cytokine signalling coming
from bone marrow stromal cells to support proliferation and
survival of malignant cells in MPN. Recently, Manshouri
et al. have demonstrated that humoral factors secreted by the
bone marrow stromal cells protect malignant cells carrying
JAK2V617F from the therapeutic eﬀect of the JAk2 inhibitors
[44]. Thus, combination of JAK2 inhibitors and interferon
alpha could be a more eﬃcient therapeutic regimen to treat
MPN patients than only JAK2 inhibitors.
Other immunomodulatory drugs are also been tested in
MPN patients, mainly in those with myelofibrosis. Thalido-
mide and lenalidomide with or without prednisone have
shown eﬃcacy to inhibit the increased cytokine production
in these patients, decreasing the spleen size, myelofibrosis,
and inhibiting angiogenesis [45]. Pomalidomide, another
analogue, is currently being evaluated with or without pred-
nisone in large clinical trials to treat patients with myelofi-
brosis [46]. These immunomodulatory drugs are candidates
to be associated to JAK2 inhibitors as targeting therapy in
patients with MPN.
Classical therapies, as hydroxycarbamide, are also eﬀec-
tive to treat patients with MPN, not only as cytoreduction
therapy but also as therapy to decrease the JAK2V617F load.
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Table 1: Current therapies for BCR-ABL1 negative MPN patients to be combined with JAK2 inhibitors.










Verstovsek et al. [29]
TG101348 or
SAR302503
JAK2, FLT3 Reduction in splenomegaly
JAK2V617F load
significantly reduced
Pardanani et al. [34]
CYT387 JAK2, JAK1, TYK2
In a murine model,
normalized erythrocytes,





Tyner et al. [35]
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JAK2, FLT3 Reduction in splenomegaly
JAK2V617F load no
reduced
Hexner et al. [36]






Unknown Kiladjian et al. [43]
Thalidomide Stromal cells Inhibition of angiogenesis Unknown Jabbour et al. [45]
Lenalidomide Stromal cells Inhibition of angiogenesis Unknown Jabbour et al. [45]
Pomalidomide Stromal cells Inhibition of angiogenesis Unknown Begna et al. [46]
Other
Hydroxycarbamide JAK2 mutant burden Inhibition of proliferation
JAK2V617F load
significantly reduced








Unknown Wang et al. [26]
Recently, Besses et al. have shown that hydroxycarbamide can
reduce the JAK2 mutant load to more than 50% in untreated
patients diagnosed with PV and TE [47]. This eﬀect has syn-
ergy with the therapeutic eﬀect of JAK2 inhibitors, making
hydroxycarbamide a candidate therapy to be combined with
JAK2 inhibitors.
JAK2 inhibitors are eﬀective to alleviate clinical symp-
toms in patients with BCR-ABL negativeMPN. Combination
with other therapies which show synergy and other biological
properties than JAK2 inhibitors is promising as the most ef-
fective therapy in these disorders (Table 1).
3. Final Remarks
JAK2 is a tyrosine kinase gene which plays an essential role
in the development of normal haematopoiesis and in the
cytokine signalling pathway involving STAT3 and STAT5 pro-
teins. Hyperactivation of JAK2 occurs in MPN by diﬀerent
genetic mechanisms. JAK2 inhibitors have been designed to
suppress the cytokine cascade initiated by the activation of
JAK2, independently of the underlying genetic mechanism.
In phase II/III of clinical trials, JAK2 inhibitors are eﬃcient
to control clinical symptoms and to improve quality of life.
Recently, it has been demonstrated that JAK2 can also be
located in the nucleus of cells, where it plays a role in the
transcriptional control of genes regulated by HP1a. Whether
JAK2 inhibitors may have a role in the suppression of the
nuclear role of JAK2 or not is at the moment unknown, but
it opens new insights for the combined use of epigenetic
therapy with JAK2 inhibitors for the treatment of MPN.
Recently, it has also been demonstrated that JAK2 inhi-
bitors are unable to target uncommitted hematopoietic pro-
genitors responsible of the initiation of the myeloprolifera-
tive disease. It is expected that, in order to cure the MPN dis-
ease, JAK2 inhibitors should be combined with other drugs
to target simultaneously diﬀerent pathways and to target the
initiator hematopoietic LSK positive cell population inMPN.
Taking advantage of the inhibition of the cytokine cas-
cade of JAK2 inhibitors, these compounds are going to be
used not only to treat patients with MPN, but also patients
with autoimmune diseases as rheumatoid arthritis, Crohn’s
disease, or Colitis ulcerosa.
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